Nexterone is an intravenous form of amiodarone, a powerful antiarrhythmic drug used to treat life-threatening heart rhythm problems. Specifically, it is used for ventricular fibrillation (when the heart’s lower chambers quiver chaotically instead of pumping) and ventricular tachycardia (when those chambers beat dangerously fast). These are cardiac emergencies, and Nexterone is given in hospitals or by emergency medical teams when other treatments have failed or when the situation is immediately life-threatening.
What Nexterone Treats
Nexterone is reserved for two specific types of dangerous heart rhythms that originate in the ventricles, the heart’s main pumping chambers. In ventricular fibrillation, electrical signals become so disorganized that the heart can’t pump blood at all. In hemodynamically unstable ventricular tachycardia, the heart beats so fast that blood pressure drops to dangerous levels and organs begin losing their blood supply. Both conditions can be fatal within minutes without intervention.
This is not a medication prescribed for everyday heart rhythm issues like atrial fibrillation or occasional palpitations. It is a last-line treatment used when a patient’s heart rhythm is actively threatening their life. In cardiac arrest situations, the American Heart Association’s emergency protocols include amiodarone as a key drug, with an initial 300 mg bolus followed by a second 150 mg dose if needed.
How Nexterone Differs From Other IV Amiodarone
Amiodarone has been available as an IV injection for years, but older formulations contain two inactive ingredients, polysorbate 80 and benzyl alcohol, that are linked to drops in blood pressure during infusion. Nexterone was developed specifically to remove those ingredients. Instead, it uses a cyclodextrin-based solubilizing agent that dissolves the drug without those problematic additives.
This matters because patients receiving IV amiodarone are already in a fragile cardiovascular state. In clinical studies of the older formulation, about 16% of patients experienced drug-related low blood pressure. By reformulating the solution, Nexterone aims to reduce that risk, though blood pressure drops can still occur with the active drug itself. About 3% of patients in studies needed their infusion adjusted because of low blood pressure, and less than 2% had to stop treatment entirely for that reason.
How It Works in the Heart
Nexterone is unusually versatile for a heart rhythm drug. Most antiarrhythmics target one specific electrical pathway in the heart. Amiodarone affects nearly all of them. It blocks the flow of sodium, potassium, and calcium through heart cell channels, and it also dampens the effect of adrenaline on the heart. Each of these actions contributes to slowing and stabilizing the heart’s electrical activity in a different way.
When given intravenously, the drug’s most immediate effects center on the AV node, the electrical gateway between the upper and lower chambers of the heart. It slows conduction through that node and makes it less responsive to rapid, chaotic signals. This is why IV amiodarone can quickly interrupt the abnormal circuits that drive ventricular fibrillation and ventricular tachycardia, even when other drugs have failed.
How It Is Given
Nexterone is always administered through an IV line in a monitored medical setting. The infusion follows a specific staged approach over the first 24 hours. It begins with a rapid loading dose of 150 mg delivered over 10 minutes. This is followed by a slower infusion of 360 mg over the next 6 hours, then 540 mg over the remaining 18 hours. After the first day, the infusion typically continues at a lower maintenance rate of about 720 mg per 24 hours.
If a patient has a breakthrough episode of ventricular fibrillation or unstable ventricular tachycardia during the infusion, an additional 150 mg can be given over 10 minutes. This supplemental dose is delivered slowly to minimize the chance of blood pressure dropping further. Higher concentrations of the drug require a central venous catheter, a larger IV line placed in a major vein, rather than a standard peripheral IV.
Potential Side Effects
The most common problem during Nexterone infusion is low blood pressure, which affected about 16% of patients in clinical studies. This makes sense given the drug’s broad effects on the heart’s electrical and pumping activity. In most cases, the drop in blood pressure can be managed by adjusting the infusion rate.
Other side effects reported in studies include:
- Slow heart rate (bradycardia): the same mechanism that stops dangerous fast rhythms can also slow the heart too much
- Lung complications: about 2% of patients developed acute respiratory distress syndrome during treatment lasting 48 hours or more
- Cardiac arrest or shock: reported in roughly 1% of patients, reflecting both a drug effect and the severity of the underlying condition being treated
- Digestive symptoms: vomiting and diarrhea, each occurring in fewer than 2% of patients
Because this drug is used in immediately life-threatening situations, the risk-benefit calculation is different from medications taken at home. The side effects are serious, but the conditions Nexterone treats are fatal without intervention.
Who Should Not Receive Nexterone
Nexterone is not appropriate for people with certain pre-existing heart conduction problems, particularly severe sinus node dysfunction (where the heart’s natural pacemaker doesn’t fire properly) or advanced heart block (where electrical signals can’t travel normally from the upper to lower chambers). In these conditions, the drug’s ability to slow conduction could cause the heart to stop entirely. People with a known sensitivity to amiodarone or iodine should also not receive it, since the amiodarone molecule contains iodine.
Patients who receive Nexterone in an emergency are closely monitored with continuous heart rhythm tracking and frequent blood pressure checks. Because amiodarone stays in the body for an exceptionally long time, with tissue stores that can take weeks or months to clear, its effects and potential interactions with other medications can persist long after the IV infusion ends.